Skip to main content

Pharmaceuticals

Enabling quick and smart access to Pharmaceuticals ingredients, we bring API expertise with a worldwide sourcing, and have a certified Excipients experience. Either you are looking for Veterinary API’s, Human API’s, Excipients, API Impurities, you can find them quickly by browsing our online catalog.

Pharmaceuticals

Filters
Refine your search
CLEAR ALL
Actylis
Excipients for injectable formulations. It is recommended for pharmaceutical applications.Benefits:
  • Acts as buffering agents/pH modifiers
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc) 
Actylis
Preservative and antimicrobial excipient used in injectable formulations.Benefits:
  • Controlled metallic impurities
  • Maintains low level of endotoxins with the bioburden limits- BET/MLT
Actylis
Excipients used in injectable formulations. It acts as a preservative/antimicrobial. 
Actylis
Solvent/co-solvent for pharmaceutical injectable formulations. It has a strong control on all possible impurities along with ICH Q3D compliance for R&D to commercial manufacturing.Benefits:
  • It maintains low level of endotoxins with the bioburden limits- BET/MLT
  • Controlled metallic impurities
  •  Developed for…
Actylis
Excipient developed for injectable formulations. It functions as a preservative/antimicrobial. Benefits:
  • Maintains a low level of endotoxins with the bioburden limits (BET/MLT etc)
Actylis
Excipient specially developed for solid and semi-solid dosage forms. It is an antioxidant and reducing agent used in injectable formulations.Benefits:
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc)
  • DMF Filed - CDE # F20200000189
Actylis
Antioxidant and reducing agent used in injectable formulations. t is an excipient designed for solid and semi-solid dosage forms. Benefits:
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc)
  • DMF Filed - CDE # F20200000189
Actylis
Excipient designed for solid and semi-solid dosage forms. Antioxidant and reducing agent developed for injectable formulations.Benefits:
  • DMF Filed - CDE # F20200000189
  • Maintains low level of endotoxins with the bioburden limits (BET/MLT etc)
Actylis
Excipient developed for use in pharmaceutical injections. Benefits:
  • It possesses characteristic aromatic odor
  • It complies with USP specifications